NVO Jan 2025 185.000 call
| Previous close | 3.1000 |
| Open | 3.1500 |
| Bid | 2.7900 |
| Ask | 3.2500 |
| Strike | 185.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.1000 - 3.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 204 |
GlobeNewswireNovo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
FLOW kidney outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 1.0 mg in people with type 2 diabetes1SELECT cardiovascular outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 2.4 mg in people with obesity and established cardiovascular disease, without diabetes2STEP HFpEF trial programme data evaluating efficacy and safety of once-weekly semaglutide 2.4 mg in people with obesity-related heart failure with preserved ejection fraction (HFpEF), w
Barrons.comNew Weight-Loss Drugs and Devices Are Coming This Week
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.
Investor's Business DailyTop Weight-Loss Rivals Share This Risk After Eye-Popping Runs
Popular weight-loss drugs have boosted Novo Nordisk and Eli Lilly. After huge gains, the drugmakers' stocks now face this risk.
